|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: DENND2D |
Gene summary for DENND2D |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | DENND2D | Gene ID | 79961 |
| Gene name | DENN domain containing 2D | |
| Gene Alias | DENND2D | |
| Cytomap | 1p13.3-p13.2 | |
| Gene Type | protein-coding | GO ID | GO:0008150 | UniProtAcc | A0A024R0H5 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 79961 | DENND2D | LZE4T | Human | Esophagus | ESCC | 1.30e-05 | 1.18e-01 | 0.0811 |
| 79961 | DENND2D | LZE7T | Human | Esophagus | ESCC | 1.37e-05 | 3.55e-01 | 0.0667 |
| 79961 | DENND2D | LZE24T | Human | Esophagus | ESCC | 5.27e-16 | 3.41e-01 | 0.0596 |
| 79961 | DENND2D | LZE6T | Human | Esophagus | ESCC | 3.70e-03 | 2.37e-01 | 0.0845 |
| 79961 | DENND2D | P2T-E | Human | Esophagus | ESCC | 6.97e-15 | 2.54e-01 | 0.1177 |
| 79961 | DENND2D | P5T-E | Human | Esophagus | ESCC | 9.44e-05 | 4.89e-02 | 0.1327 |
| 79961 | DENND2D | P8T-E | Human | Esophagus | ESCC | 8.14e-17 | 2.43e-01 | 0.0889 |
| 79961 | DENND2D | P9T-E | Human | Esophagus | ESCC | 2.84e-04 | 1.24e-01 | 0.1131 |
| 79961 | DENND2D | P10T-E | Human | Esophagus | ESCC | 1.38e-08 | 1.07e-01 | 0.116 |
| 79961 | DENND2D | P12T-E | Human | Esophagus | ESCC | 1.04e-20 | 4.19e-01 | 0.1122 |
| 79961 | DENND2D | P15T-E | Human | Esophagus | ESCC | 1.30e-05 | 6.04e-02 | 0.1149 |
| 79961 | DENND2D | P16T-E | Human | Esophagus | ESCC | 2.40e-05 | 7.60e-02 | 0.1153 |
| 79961 | DENND2D | P20T-E | Human | Esophagus | ESCC | 3.54e-10 | 1.70e-01 | 0.1124 |
| 79961 | DENND2D | P21T-E | Human | Esophagus | ESCC | 1.58e-07 | 2.05e-01 | 0.1617 |
| 79961 | DENND2D | P23T-E | Human | Esophagus | ESCC | 5.22e-18 | 3.81e-01 | 0.108 |
| 79961 | DENND2D | P24T-E | Human | Esophagus | ESCC | 9.92e-10 | 1.57e-01 | 0.1287 |
| 79961 | DENND2D | P26T-E | Human | Esophagus | ESCC | 9.34e-13 | 1.69e-01 | 0.1276 |
| 79961 | DENND2D | P27T-E | Human | Esophagus | ESCC | 4.99e-09 | 1.34e-01 | 0.1055 |
| 79961 | DENND2D | P28T-E | Human | Esophagus | ESCC | 6.50e-14 | 2.12e-01 | 0.1149 |
| 79961 | DENND2D | P30T-E | Human | Esophagus | ESCC | 9.53e-11 | 2.49e-01 | 0.137 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| DENND2D | SNV | Missense_Mutation | rs774863479 | c.1187G>A | p.Arg396Gln | p.R396Q | Q9H6A0 | protein_coding | tolerated(0.71) | benign(0.44) | TCGA-B6-A0RS-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
| DENND2D | SNV | Missense_Mutation | c.452N>T | p.Pro151Leu | p.P151L | Q9H6A0 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-B6-A1KN-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
| DENND2D | SNV | Missense_Mutation | c.176N>C | p.Val59Ala | p.V59A | Q9H6A0 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-D8-A1XR-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin+cyclophosphamide | SD | |
| DENND2D | SNV | Missense_Mutation | c.736C>G | p.Gln246Glu | p.Q246E | Q9H6A0 | protein_coding | tolerated(0.2) | benign(0.015) | TCGA-E2-A10C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | |
| DENND2D | SNV | Missense_Mutation | rs757235164 | c.1108C>A | p.Gln370Lys | p.Q370K | Q9H6A0 | protein_coding | tolerated(0.15) | benign(0.003) | TCGA-OL-A66P-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | CR |
| DENND2D | SNV | Missense_Mutation | novel | c.539N>T | p.Ser180Phe | p.S180F | Q9H6A0 | protein_coding | deleterious(0) | probably_damaging(0.975) | TCGA-MA-AA41-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| DENND2D | SNV | Missense_Mutation | novel | c.172N>T | p.Leu58Phe | p.L58F | Q9H6A0 | protein_coding | tolerated(0.08) | benign(0.007) | TCGA-VS-A8QC-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | paclitaxel | PD |
| DENND2D | SNV | Missense_Mutation | c.1027N>G | p.Lys343Glu | p.K343E | Q9H6A0 | protein_coding | tolerated(0.25) | benign(0) | TCGA-A6-6138-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| DENND2D | SNV | Missense_Mutation | rs368968192 | c.826G>A | p.Ala276Thr | p.A276T | Q9H6A0 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| DENND2D | SNV | Missense_Mutation | c.559T>C | p.Phe187Leu | p.F187L | Q9H6A0 | protein_coding | tolerated(0.18) | probably_damaging(0.998) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |